Please login or register to print this page.

VIEW TAGS

Articles tagged ‘warfarin’

November 15, 2012

New app for warfarin monitoring

A new app has been released which helps patients undergoing oral anticoagulant therapy (OAT) monitor and record their warfarin usage and international normalised ratio (INR) as part of their daily routine.

read more

July 24, 2012

Study evaluates dabigatran in mechanical heart valve patients

The design of the RE-ALIGN study, the first study to evaluate a novel oral anticoagulant as alternative to warfarin for use in patients with mechanical heart valves requiring anticoagulation therapy, has been published recently by the American Heart Journal.1

read more

April 18, 2012

New oral anticoagulants eclipse warfarin in cost savings

Usage of the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, and apixaban, may be associated with lower medical costs (excluding drug costs) relative to warfarin, according to results from the RE-LY, ROCKET-AF, and ARISTOTLE clinical trials. These were presented at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Session, held recently in Chicago.

read more

November 3, 2011

Aspirin unsafe and ineffective for stroke prevention in AF

Aspirin increases the risk of bleeding without decreasing the risk of stroke/thromboembolism sufficiently in patients with atrial fibrillation (AF), according to a study1 published recently in Thrombosis and Haemostasis.

read more

September 7, 2011

DABIGATRAN LICENSED IN UK

A new oral anticoagulant, dabigatran etexilate (Pradaxa®, Boehringer Ingelheim), has been made available in the UK. Following the EU licence for dabigatran, granted on 1st August 2011,1 a recommended dose of 150 mg twice daily is now licensed in the UK for the prevention of stroke and systemic embolism in eligible adult patients with AF.

read more

August 2, 2011

DABIGATRAN – COST EFFECTIVE?

The superiority of dabigatran to warfarin, as reported by the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, may be offset by its cost, according to an editorial1 published recently in Circulation.

read more

September 7, 2009

Atrial Fibrillation high on ESC agenda

A record number of 31,371 delegates attended the European Society of Cardiology (ESC)Congress in Barcelona this week. Clinical trials in atrial fibrillation were among the most well attended sessions, receiving worldwide news coverage within minutes of presentation. Principal among these were RE-LY and PLATO, details of which we feature here.

read more

June 8, 2009

Device closure of LAA and stroke prevention

Use of the WATCHMAN® left atrial appendage (LAA) device may be an alternative to warfarin to prevent stroke in patients with atrial fibrillation.

read more

« Newer articles

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.